JP2025502861A - 抗ＦＸＩ／ＦＸＩａ抗体を含む医薬組成物及びその使用 - Google Patents

抗ＦＸＩ／ＦＸＩａ抗体を含む医薬組成物及びその使用 Download PDF

Info

Publication number
JP2025502861A
JP2025502861A JP2024540670A JP2024540670A JP2025502861A JP 2025502861 A JP2025502861 A JP 2025502861A JP 2024540670 A JP2024540670 A JP 2024540670A JP 2024540670 A JP2024540670 A JP 2024540670A JP 2025502861 A JP2025502861 A JP 2025502861A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
fxi
sucrose
histidine
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024540670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025502861A5 (https=
Inventor
立君 沈
志▲龍▼ ▲趙▼
磊 李
辰翔 ▲湯▼
Original Assignee
上▲海▼▲邁▼晋生物医▲薬▼科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上▲海▼▲邁▼晋生物医▲薬▼科技有限公司 filed Critical 上▲海▼▲邁▼晋生物医▲薬▼科技有限公司
Publication of JP2025502861A publication Critical patent/JP2025502861A/ja
Publication of JP2025502861A5 publication Critical patent/JP2025502861A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2024540670A 2022-01-05 2023-01-05 抗ＦＸＩ／ＦＸＩａ抗体を含む医薬組成物及びその使用 Pending JP2025502861A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202210006206.X 2022-01-05
CN202210006206 2022-01-05
CN202210053441.2 2022-01-18
CN202210053441 2022-01-18
PCT/CN2023/070573 WO2023131213A1 (zh) 2022-01-05 2023-01-05 一种包含抗FXI/FXIa抗体的药物组合物及其用途

Publications (2)

Publication Number Publication Date
JP2025502861A true JP2025502861A (ja) 2025-01-28
JP2025502861A5 JP2025502861A5 (https=) 2026-01-15

Family

ID=87073189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024540670A Pending JP2025502861A (ja) 2022-01-05 2023-01-05 抗ＦＸＩ／ＦＸＩａ抗体を含む医薬組成物及びその使用

Country Status (6)

Country Link
US (1) US20250179213A1 (https=)
EP (1) EP4461749A4 (https=)
JP (1) JP2025502861A (https=)
CN (1) CN118382643A (https=)
TW (1) TW202333789A (https=)
WO (1) WO2023131213A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066481B2 (en) * 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
TW201802121A (zh) * 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
US20190367636A1 (en) * 2017-01-19 2019-12-05 Bayer Pharma Aktiengesellschaft Novel stable formulation for fxia antibodies
EP3626266A4 (en) * 2017-05-16 2021-04-07 Jiangsu Hengrui Medicine Co., Ltd. CTLA4 ANTIBODY PHARMACEUTICAL COMPOSITION AND USES THEREOF
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
PE20210462A1 (es) * 2018-07-05 2021-03-08 Bayer Ag METODO PARA LA PRODUCCION DE GRANULOS LIOFILIZADOS QUE COMPRENDEN UN ANTICUERPO ANTI-FACTOR XIa (FXIa) DE LA COAGULACION
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
EP3898700A1 (en) * 2018-12-18 2021-10-27 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
KR20210151774A (ko) * 2019-04-16 2021-12-14 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-FXI/FXIa 항체 및 그 용도
US20230071973A1 (en) * 2019-12-20 2023-03-09 Anthos Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof

Also Published As

Publication number Publication date
EP4461749A1 (en) 2024-11-13
CN118382643A (zh) 2024-07-23
TW202333789A (zh) 2023-09-01
US20250179213A1 (en) 2025-06-05
EP4461749A4 (en) 2025-03-26
WO2023131213A1 (zh) 2023-07-13

Similar Documents

Publication Publication Date Title
CN110538321B (zh) 一种cd47抗体药物组合物及其用途
CN110198739B (zh) 一种pd-l1抗体药物组合物及其用途
JP7807081B2 (ja) 抗ＦＸＩ／ＦＸＩａ抗体、その抗原結合断片と医薬用途
JP2026048838A (ja) 高濃度抗ｃ５抗体配合物
US20220031842A1 (en) Lag-3 antibody pharmaceutical composition and use thereof
JP2023515423A (ja) 抗ｉｌ－４ｒ抗体医薬組成物及びその使用
KR20230044448A (ko) 항-pd-1 항체 약학적 조성물 및 이의 용도
JP2023109987A (ja) 抗ヒトｇｐｖｉ抗体を用いた血小板凝集の阻害
CN111375059B (zh) 一种抗gitr抗体药物组合物及其用途
US20210261663A1 (en) Anti-tim3 antibody pharmaceutical composition and use thereof
CN113507938A (zh) 包含抗il-5抗体的药物组合物及其用途
KR20240035835A (ko) 항-angptl3 항체 또는 이의 항원 결합 단편의 약학적 조성물 및 이의 응용
EP4257603A1 (en) Pharmaceutical composition comprising anti-connective tissue growth factor antibody
JP2022513671A (ja) Ｃｄ４０抗体医薬品組成物およびその使用
US20250179213A1 (en) Pharmaceutical composition comprising anti-fxi/fxia antibody and use thereof
KR102962504B1 (ko) Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
EA052061B1 (ru) Фармацевтическая композиция антитела против angptl3 или его антигенсвязывающего фрагмента и ее применение
HK40047597A (en) Anti-tim3 antibody pharmaceutical composition and use thereof
HK40069564B (zh) 抗fxi/fxia抗体、其抗原结合片段及医药用途
HK40059623A (en) Pharmaceutical composition containing antibody against il-5 and use thereof
HK40013346B (en) Pd-l1 antibody pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260105